Welcome to our dedicated page for Becton, Dickinson and Co. news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton, Dickinson and Co. stock.
Becton, Dickinson and Company (BD) (NYSE: BDX) is a global medical technology firm committed to advancing healthcare through the development, manufacture, and sale of a broad range of medical supplies, devices, laboratory equipment, and diagnostic products. Established in 1897, BD's mission is to enhance medical discovery, diagnostics, and care delivery. The company's extensive product portfolio serves healthcare institutions, physicians, life science researchers, and others across the globe.
BD is noted for being the world’s largest manufacturer and distributor of medical surgical products such as needles, syringes, and sharps-disposal units. The company also excels in producing pre-filled devices, diagnostic instruments, and reagents. Furthermore, BD offers sophisticated flow cytometry and cell-imaging systems. BD Medical represents nearly half of the company's total business, while BD Life Sciences and BD Interventional contribute 27% and 24% of the 2023 revenue, respectively. Impressively, international revenue accounts for 43% of the company's business.
Recent achievements and projects underscore BD's commitment to innovation and sustainability. The company recently collaborated with health care institutions in Denmark to explore recycling used blood collection tubes, achieving significant environmental advancements without compromising safety or quality.
In a pivotal development, BD announced the global commercial release of new cell sorters, enabling researchers in fields such as cell biology, cancer research, and immunology to gain new insights. The BD FACSDiscover™ S8 Cell Sorters incorporate groundbreaking technologies like BD CellView™ Image Technology and BD SpectralFX™ Technology, significantly enhancing real-time imaging and spectral flow cytometry.
BD also reported robust financial performance for the second quarter of fiscal 2024, highlighting strong operating margins and cash flow. This success led to an optimistic outlook and an increased earnings guidance, demonstrating the company’s resilience and strategic execution.
Further solidifying its market position, BD is set to acquire Edwards Lifesciences' Critical Care product group for $4.2 billion. This acquisition expands BD’s portfolio in smart connected care solutions, leveraging advanced AI algorithms for better patient outcomes and adding significant value to its operations.
With a presence in almost every country and a workforce of over 70,000 employees, BD remains dedicated to advancing the world of health. The company works closely with customers and partners globally to address complex health challenges, enhance clinical outcomes, and expand access to healthcare.
Vicarious Surgical Inc. and D8 Holdings Corp. have reached a definitive business combination agreement, transitioning Vicarious to publicly trade under the new ticker symbol RBOT post-closing on the NYSE. This merger aims to enhance surgical efficiency and patient outcomes through Vicarious's advanced robotics technology, which provides significant cost savings compared to legacy systems. The transaction could yield up to $460 million in gross proceeds, supported by a $115 million private placement. The merger is anticipated to finalize by Q3 2021, pending D8 shareholder approval.
BD (Becton, Dickinson and Company) announced it has received 510(k) clearance from the FDA for its new Pristine™ Long-Term Hemodialysis Catheter, set to be available in the U.S. in May 2021. This innovative catheter features a unique side-hole free symmetric Y-Tip™ distal lumen design aimed at improving patient outcomes by minimizing complications such as thrombus formation. Following a feasibility study involving 45 patients, primary patency rates were reported at 100.0% at 60 days and 90.9% at 180 days, indicating promising performance for patients requiring hemodialysis.
On April 13, 2021, BD (NYSE: BDX) announced that its BD MAX™ Molecular Multi-Drug Resistant Tuberculosis (MDR-TB) Assay has been recognized by the WHO as part of the moderate complexity automated NAAT class for TB diagnostics. This assay allows simultaneous detection of the TB bacteria and mutations for resistance to isoniazid (INH) and rifampicin (RIF). BD emphasizes its commitment to combating antimicrobial resistance and improving TB treatment, marking a significant milestone for the product. The BD MAX™ system is already CE marked and available in Europe and beyond.
BD (Becton, Dickinson and Company) (NYSE: BDX) will announce its financial results for Q2 of fiscal year 2021 on May 6, 2021, at approximately 6:00 a.m. ET. The results will be shared via a press release and presentation materials on its investors' website. Following this, a conference call will be held at 8:00 a.m. ET, and can be accessed through a dedicated telephone line. The webcast will be available for replay until May 13, 2021.
BD (Becton, Dickinson and Company) is set to invest $65 million in a new 120,000 square-foot facility in Tucson, Arizona, aimed at enhancing its supply chain capabilities. The facility will serve as a final-stage manufacturing and sterilization center, expected to be operational by mid-2022, and create approximately 40 new jobs. BD's initiative is projected to generate a $122 million economic impact over the next decade, reinforcing the company's commitment to public health and operational efficiency.
On April 1, 2021, BD (Becton, Dickinson and Company) announced that the FDA granted Emergency Use Authorization (EUA) for its rapid antigen test, the BD Veritor™ Plus System, to screen asymptomatic individuals for SARS-CoV-2 through serial testing. This authorization allows testing twice over two to three days, enhancing the detection of COVID-19 and supporting efforts to return to normalcy. The system facilitates testing in various settings like schools and workplaces, addressing public health reporting challenges through a collaboration with ImageMover for efficient data management.
BD (Becton, Dickinson and Company) announces that the FDA has granted emergency use authorization (EUA) for a rapid antigen test capable of detecting SARS-CoV-2, influenza A, and influenza B in a single test. The BD Veritor™ Plus System test will be available this summer, enabling healthcare providers to distinguish between these viral infections quickly. The test delivers results in about 15 minutes, streamlining the diagnostic process during the flu season. BD currently has over 70,000 active testing systems across multiple healthcare settings.
BD (Becton, Dickinson and Company) has partnered with ImageMover to launch a mobile app that enhances the reporting of SARS-CoV-2 antigen testing results from the BD Veritor™ Plus System. This app aims to simplify data collection at everyday settings like schools and businesses, addressing the challenges of managing test subject demographics and reporting. Available immediately, the ImageMover app provides secure, automated reporting to health authorities, streamlining the process for organizations lacking sophisticated IT infrastructure. The partnership supports BD's innovation in COVID-19 testing solutions.
BD (Becton, Dickinson and Company) has acquired GSL Solutions, Inc., a company specializing in smart medication devices that enhance the security and efficiency of medication storage and compliance. This acquisition aims to bolster BD's medication management capabilities in retail pharmacies and outpatient settings. BD sees this as a strategic move to address growing market demands for automated tracking of medications. GSL's technology includes RFID-based systems that improve operational efficiency and reduce patient wait times. The transaction is expected to be immaterial financially.
BD (Becton, Dickinson and Company) (NYSE: BDX) announced a collaboration with Scanwell Health to develop an at-home rapid test for SARS-CoV-2. This new test will utilize a BD antigen test paired with Scanwell's mobile app, offering step-by-step instructions for sample collection. Users can analyze results using their device's camera, with plans for automated reporting to health agencies. The initiative aims to enhance COVID-19 testing accessibility. BD has played a significant role in the COVID-19 response, providing a range of diagnostic solutions.
FAQ
What is the current stock price of Becton, Dickinson and Co. (BDX)?
What is the market cap of Becton, Dickinson and Co. (BDX)?
What does Becton, Dickinson and Company (BD) specialize in?
What are BD's main business segments?
What recent projects has BD undertaken?
How much of BD's revenue comes from international markets?
What significant acquisition has BD announced recently?
How many employees does BD have?
Where can I find more information about BD's financial performance?
What is the significance of the BD FACSDiscover™ S8 Cell Sorters?
Which regulatory body recently issued a safety communication regarding syringes?
What is BD's approach to sustainability?
